ArticleFrontiers in pharmacology2023

Suvorexant, an FDA-approved dual orexin receptor antagonist, reduces oxycodone self-administration and conditioned reinstatement in male and female rats.

Jessica M Illenberger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.